Pharmaceuticals, Biotechnology and Life Sciences
OptiBiotix health has signed a manufacturing, supply, and profit sharing deal with Sacco, one of Europe’s leading suppliers of probiotics ingredients.
Valisek, a joint venture between ValiRx, a clinical stage biotechnology company and Tangent Reprofiling Limited, plans to add a third clinical site, in Tbilisi, Georgia.
Innate Pharma has reported its consolidated financial results for the year ended December 31, 2016.
Swedish Orphan Biovitrum AB known as Sobi said Tuesday that the FDA has approved increased shelf life and extended out-of-refrigeration for Orfadin capsules.
IDMC has recommended that all three doses continue to be tested in the ongoing Phase 2b trial for BGS-649, an inhibitor for obese men with hypogonadotropic hypoganadism.
Herantis Pharma clinical study with the company’s innovative gene therapy investigational product Lymfactin for the treatment of secondary lymphedema has advanced to highest planned dose level owing to good reported safety.
Futura Medical has filed a new formulation patent for its topical gel for the treatment of erectile dysfunction, with the UK Intellectual Property Office in connection with MED2002.
AB Science has recruited 350 patients for the phase 3 study (AB07015) in severe persistent asthma uncontrolled by oral corticosteroids, for which the final results will be available at the end of 2017.
Abzena, a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, has reported that one of the ‘Abzena inside’ Composite Human Antibody products for the treatment of neurodegenerative conditions has moved to Phase II clinical trial.
Novartis has reported new analysis showing that moderate-to-severe psoriasis patients treated with Cosentyx (secukinumab) rapidly regain clear or almost clear skin (Psoriasis Area Severity Index, PASI 90 to 100) following relapse during a treatment pause. Also showed no anti-secukinumab antibodies were observed during retreatment.